Citius Oncology, Inc. Common Stock (CTOR)

• Market cap: $69.7M
• 1 day: -7.73%
• 5 days: -8.59%
• 1 month: -1.20%
• 3 months: -38.87%
• 6 months: -69.43%
• Year to date: -69.43%
• 1 year: -69.43%
• 5 years: -69.43%
• 10 years: -69.43%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.05% more ownership

Funds ownership: 0% [Q2] → 0.05% (+0.05%) [Q3]

54% less funds holding

Funds holding: 13 [Q2] → 6 (-7) [Q3]

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

100% less capital invested

Capital invested by funds: $46.1M [Q2] → $31.7K (-$46M) [Q3]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 207% upside
• Avg. target: $3 207% upside
• High target: $3 207% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Michael Okunewitch 33% 1-year accuracy 2 / 6 met price target

207% upside $3

Buy Initiated

27 Nov 2024